Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oasmia Pharmaceutical AB (publ)
  6. News
  7. Summary
    OASM   SE0000722365

OASMIA PHARMACEUTICAL AB (PUBL)

(OASM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oasmia Pharmaceutical : Cantrixil positive Phase I trial data published in the journal Cancers

06/30/2021 | 01:01am EDT
  • Study demonstrates Cantrixil’s potential to prolong survival in advanced ovarian cancer

Stockholm, Sweden, 30 June 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announces that the results from a Phase I open-label study (NCT02903771) of the investigational drug candidate Cantrixil (TRX-E-002-1) have been published in Cancers, a peer-reviewed, open access journal of oncology. 

The paper entitled ‘Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results’ can be accessed online at the following link: https://www.mdpi.com/2072-6694/13/13/3196/pdf.

Oasmia acquired the exclusive global development rights for the Cantrixil ovarian cancer program from Kazia Therapeutics Ltd earlier this year. Top-line data from the Phase I study previously reported by Kazia Therapeutics Ltd in December 2020 and presented at the American Association of Cancer Research (AACR) annual meeting in April 2021 confirmed that the Phase I study met its primary endpoints, establishing clinical proof of concept.

The study was conducted at sites in the USA and Australia under the leadership of clinical trial’s Principal Investigator, Jermaine Coward, Associate Professor, ICON Cancer Centre, located in Brisbane, Australia. The study aimed to define the maximum tolerated dose, tolerability, and antitumor activity of Cantrixil when administered via an intraperitoneal (IP) port. Cantrixil was well tolerated even in patients with heavily pre-treated disease.

The study demonstrates the potential for prolonged survival in advanced ovarian cancer by inducing ovarian cancer stem cells’ death and sensitizing cancer cells to standard chemotherapy with IP-administered Cantrixil.

Dr. Heidi B. Ramstad, CMO of Oasmia, commented: “These data are encouraging and has demonstrated the potential for prolonged survival in some patients with advanced ovarian cancer. By inducing ovarian cancer stem cell death and sensitizing cancer cells to standard chemotherapy, Cantrixil may improve survival outcomes in this patient population. Ovarian cancer remains one of the most aggressive cancers and are proven difficult to treat in advanced stages. We look forward to the forthcoming Phase 2 trial investigating Cantrixil in combination with first-line chemotherapy with an aim to improve survival rates in ovarian cancer.”

For More Information: 

Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@oasmia.com

Consilium Strategic Communications (For Oasmia)
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700 
E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Oasmia’s most advanced program is Apealea® (paclitaxel micellar), which is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia’s proprietary drug delivery platform XR-17™ is designed to improve drug solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.

 

© Modular Finance, source Nordic Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
KAZIA THERAPEUTICS LIMITED 0.00% 1.49 End-of-day quote.28.45%
OASMIA PHARMACEUTICAL AB (PUBL) -4.68% 2.26 Delayed Quote.-42.45%
All news about OASMIA PHARMACEUTICAL AB (PUBL)
10/21OASMIA PHARMACEUTICAL : announces global settlement of all disputes with MGC Capital, form..
AQ
10/20OASMIA PHARMACEUTICAL : Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutic..
AQ
10/08OASMIA PHARMACEUTICAL (OASM) : Focused on pillars of growth
DJ
10/01OASMIA PHARMACEUTICAL : Naventus LifeScience Summit
PU
09/24OASMIA PHARMACEUTICAL : to present at Naventus Life Science Summit on September 29
AQ
09/20OASMIA PHARMACEUTICAL : Notice of Extraordinary General Meeting in Oasmia Pharmaceutical A..
AQ
09/17OASMIA PHARMACEUTICAL : signs agreement with FarmaMondo to commercialize Paclical® in Russ..
AQ
09/17Oasmia Pharmaceutical AB Signs Agreement with FarmaMondo to Commercialize Paclical® in ..
CI
09/07OASMIA PHARMACEUTICAL : Presentation på Aktiedagen Stockholm
PU
08/31OASMIA PHARMACEUTICAL : to present at Aktiedagen Stockholm on September 7
AQ
More news
Financials
Sales 2021 10,2 M 1,19 M 1,19 M
Net income 2021 -173 M -20,1 M -20,1 M
Net cash 2021 130 M 15,1 M 15,1 M
P/E ratio 2021 -5,65x
Yield 2021 -
Capitalization 1 013 M 118 M 118 M
EV / Sales 2021 86,6x
EV / Sales 2022 25,1x
Nbr of Employees 25
Free-Float 61,3%
Chart OASMIA PHARMACEUTICAL AB (PUBL)
Duration : Period :
Oasmia Pharmaceutical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OASMIA PHARMACEUTICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,26 SEK
Average target price 5,70 SEK
Spread / Average Target 152%
EPS Revisions
Managers and Directors
François R. Martelet Chief Executive Officer
Fredrik Järrsten Chief Financial Officer
Karl Anders Olof Härfstrand Chairman
Mikael Asp Chief Technology Officer
Carina Eklöw Director-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
OASMIA PHARMACEUTICAL AB (PUBL)-42.45%124
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079
ELI LILLY AND COMPANY42.84%218 640